Fulcrum Therapeutics, Inc.FULCNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P23
Within normal range
vs 5Y Ago
-0.4x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -3.77% |
| Q3 2025 | 10.75% |
| Q2 2025 | -2.44% |
| Q1 2025 | -9.29% |
| Q4 2024 | -8.40% |
| Q3 2024 | -17.79% |
| Q2 2024 | 1.85% |
| Q1 2024 | 7.54% |
| Q4 2023 | -6.07% |
| Q3 2023 | -3.51% |
| Q2 2023 | -10.39% |
| Q1 2023 | 13.72% |
| Q4 2022 | 4.36% |
| Q3 2022 | -12.53% |
| Q2 2022 | 3.15% |
| Q1 2022 | 10.86% |
| Q4 2021 | 12.48% |
| Q3 2021 | 29.07% |
| Q2 2021 | 21.59% |
| Q1 2021 | -6.29% |
| Q4 2020 | 10.45% |
| Q3 2020 | 3.17% |
| Q2 2020 | 1.68% |
| Q1 2020 | 15.01% |
| Q4 2019 | 25.44% |
| Q3 2019 | 33.26% |
| Q2 2019 | 1.39% |
| Q1 2019 | 8.66% |
| Q4 2018 | 12.52% |
| Q3 2018 | 3.11% |
| Q2 2018 | 18.65% |
| Q1 2018 | 0.00% |